Sanofi (SNY) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Downgraded | Buy → Neutral | — | Jan 16, 2026 |
| Barclays | Downgraded | Overweight → Equal-Weight | — | Jan 6, 2026 |
| Guggenheim | Downgraded | Buy → Neutral | — | Dec 9, 2025 |
| JP Morgan | Downgraded | Overweight → Neutral | — | Dec 8, 2025 |
| Jefferies | Initiated Coverage | Buy | — | Oct 27, 2025 |
| Morgan Stanley | Upgraded | Equal-Weight → Overweight | $58.00 from $56.00 | Sep 8, 2025 |
| Deutsche Bank | Upgraded | Hold → Buy | — | Sep 2, 2025 |
| JP Morgan | Upgraded | Neutral → Overweight | — | Aug 8, 2025 |
| Goldman Sachs | Initiated Coverage | Neutral | $65.00 | Mar 21, 2025 |
| Argus Research | Maintained | Buy | $60.00 from $55.00 | Jul 26, 2024 |
| Morgan Stanley | Initiated Coverage | Equal-Weight | $55.00 | Jan 23, 2024 |
| Argus Research | Maintained | Buy | $60.00 from $55.00 | Mar 27, 2023 |
Frequently asked questions
Is SNY a buy, sell, or hold?
Analysts covering Sanofi currently average a Hold rating: 3 buy, 4 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on SNY?
On Jan 16, 2026, UBS downgraded Sanofi to Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.